Facebook Linkedin RSS Twitter Youtube
Home 2021

Sarepta Therapeutics

AI Gets Gene Therapy Over the Immunity Hump
Drug Discovery

AI Gets Gene Therapy Over the Immunity Hump

Ten Life Science Analysts to Watch in 2020
A-Lists

Ten Life Science Analysts to Watch in 2020

Roche Buys Ex-U.S. Rights to Sarepta DMD Gene Therapy Candidate SRP-9001 for Up-to-$2.85B+
Genome Editing

Roche Buys Ex-U.S. Rights to Sarepta DMD Gene Therapy Candidate SRP-9001 for Up-to-$2.85B+

10 Takeover Targets to Watch This Fall
A-Lists

10 Takeover Targets to Watch This Fall

Sarepta to Acquire Myonexus for $165M, Broadening Muscular Dystrophy Gene Therapy Pipeline
Genome Editing

Sarepta to Acquire Myonexus for $165M, Broadening Muscular Dystrophy Gene Therapy Pipeline

Sarepta Acquires U.S., ex-European Rights to Lysogene MPS III Gene Therapy Candidate LYS-SAF302
News

Sarepta Acquires U.S., ex-European Rights to Lysogene MPS III Gene Therapy Candidate LYS-SAF302

FDA Lifts Holds on Epizyme Cancer Candidate, Sarepta DMD Gene Therapy
News

FDA Lifts Holds on Epizyme Cancer Candidate, Sarepta DMD Gene Therapy

What the Top 10 Biopharma CEOs Are Making
A-Lists

What the Top 10 Biopharma CEOs Are Making

Sarepta Licenses Up to Three CNS-Targeting Gene Therapies from Lacerta
Genome Editing

Sarepta Licenses Up to Three CNS-Targeting Gene Therapies from Lacerta

FDA Places Clinical Hold on Sarepta DMD Micro-Dystrophin Gene Therapy Trial
Genome Editing

FDA Places Clinical Hold on Sarepta DMD Micro-Dystrophin Gene Therapy Trial

123Page 2 of 3
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.